SIGA Technologies, Inc. (SIGA) is a pharmaceutical company. The Company is engaged in the development and commercialization of solutions for serious unmet medical needs and biothreats. The Company's lead product is Tecovirimat, also known as ST-246, an orally administered antiviral drug that targets orthopoxviruses, including smallpox. Tecovirimat is not licensed as safe or effective by the U.S. Food & Drug Administration (USFDA), it is a small-molecule drug that is being delivered to the Strategic National Stockpile under Project BioShield. For the manufacture of Tecovirimat, the Company uses the following contract manufacturing organizations: Albemarle Corporation (Albemarle), Powdersize, Inc. (Powdersize) and Catalent Pharma Solutions LLC (Catalent).